Fedra Najjar1, Thomas Owley2, Matthew W Mosconi3, Suma Jacob4, Kwan Hur5, Stephen J Guter1, John A Sweeney3, Robert D Gibbons5, Edwin H Cook1, Jeffrey R Bishop6. 1. 1 Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago , Chicago, Illinois. 2. 2 Department of Psychiatry, Rush University , Chicago, Illinois. 3. 3 Department of Psychiatry, University of Texas Southwestern Medical Center , Dallas Texas. 4. 4 Department of Psychiatry, University of Minnesota , Minneapolis, Minnesota. 5. 5 Department of Public Health Sciences, University of Chicago , Chicago, Illinois. 6. 6 Department of Experimental and Clinical Pharmacology, University of Minnesota , Minneapolis, Minnesota.
Abstract
OBJECTIVE: The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD). METHODS: Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20 mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment outcomes and drug doses. RESULTS: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genotype groups. Similarly, dosing trajectory was not significantly associated with genotype groups. CONCLUSIONS: Previous studies have identified SLC6A4 and HTR2A associations with SSRI response in patients with depression and 5-HTTLPR (SLC6A4) associations with escitalopram response in ASD. We did not observe evidence for similar relationships in this ASD study.
OBJECTIVE: The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD). METHODS: Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20 mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment outcomes and drug doses. RESULTS: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genotype groups. Similarly, dosing trajectory was not significantly associated with genotype groups. CONCLUSIONS: Previous studies have identified SLC6A4 and HTR2A associations with SSRI response in patients with depression and 5-HTTLPR (SLC6A4) associations with escitalopram response in ASD. We did not observe evidence for similar relationships in this ASD study.
Authors: Thomas Owley; Camille W Brune; Jeff Salt; Laura Walton; Steve Guter; Nelson Ayuyao; Robert D Gibbons; Bennett L Leventhal; Edwin H Cook Journal: Autism Res Date: 2010-02 Impact factor: 5.216
Authors: Susan Risi; Catherine Lord; Katherine Gotham; Christina Corsello; Christina Chrysler; Peter Szatmari; Edwin H Cook; Bennett L Leventhal; Andrew Pickles Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-09 Impact factor: 8.829
Authors: Heide Klumpp; Daniel A Fitzgerald; Edwin Cook; Stewart A Shankman; Mike Angstadt; K Luan Phan Journal: Neuroreport Date: 2014-08-20 Impact factor: 1.837
Authors: Bryan H King; Eric Hollander; Linmarie Sikich; James T McCracken; Lawrence Scahill; Joel D Bregman; Craig L Donnelly; Evdokia Anagnostou; Kimberly Dukes; Lisa Sullivan; Deborah Hirtz; Ann Wagner; Louise Ritz Journal: Arch Gen Psychiatry Date: 2009-06
Authors: Jeffrey R Bishop; Fedra Najjar; Leah H Rubin; Stephen J Guter; Thomas Owley; Matthew W Mosconi; Suma Jacob; Edwin H Cook Journal: Pharmacogenet Genomics Date: 2015-11 Impact factor: 2.089
Authors: Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller Journal: Can J Psychiatry Date: 2020-11-23 Impact factor: 5.321